Health Technology

Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research

Invitae, a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to build a global platform to help patients collect, organize, store and share their medical records digitally. The acquisition would enhance Invitae's platform by providing patients an easy-to-use, centralized hub for their genomic and clinical information, which together comprise a powerful dataset with the potential to drive research and improve healthcare decision making.

 

"Invitae is relentlessly pursuing a day when genetics is used routinely to improve healthcare for billions of people around the globe. We believe combining Ciitizen's state-of-the-art, transparent and patient-consented platform with our technologies and services will accelerate our evolution into a genome information company that informs healthcare throughout one's life. This would give us the ability to engage patients, create an innovative patient-centered data ecosystem and deliver better outcomes for everyone. Invitae views the acquisition of Ciitizen as an important part of its strategy to be the industry leader across the genetic testing, software and health information technology spaces," said Sean George, Ph.D., co-founder and CEO of Invitae.

 

"Ciitizen has already helped patients take ownership of their medical records to optimize therapy for themselves and contribute their data towards a variety of goals, including research on rare diseases," said Anil Sethi, CEO and founder of Ciitizen. "Patients leave a breadcrumb trail of records behind them, and we believe access to this real-world data is key to personalized therapeutics in the future. The combination of lifelong health history together with Invitae's world-class genetic and data services would enable a digital ecosystem of personalized services for each patient. Democratization of patient-consented data is expected to improve outcomes by providing access to third-parties for whom the patient has granted consent.  Unlike many health data companies, we operate on the premise that it's the patient's data, not ours."

 

Dr. George continued, "Genomics is currently a laboratory testing-based industry, but in the future it will look very much like an information industry. Developing an open-ended patient-centric platform of genomic, clinical and reported outcomes creates a thriving and purposeful network that truly advances healthcare. Patient control is the big differentiator at Ciitizen and at Invitae; and we believe combining forces is the right strategy for our businesses going forward."  

 

Empowering patients to combine their genomic and clinical information to improve clinical care

Invitae is working to aggregate results from the world's genetic tests into a single, easy-to-use service that makes genetic information accessible to all who can benefit from it - always with patient consent. Over the past five years, Invitae has completed 13 acquisitions that have expanded its testing menu, lowered the cost of its tests, improved its customer experience and enhanced its ability to attract partners. Invitae raised more than $1.4 billion since the beginning of 2021, in part to identify and acquire key assets that bring the company closer to delivering on its vision.

 

The addition of Ciitizen is expected to empower Invitae to more quickly extend its platform, adding a complementary patient service that streamlines the process of collecting and organizing health information from any source and uses machine learning to transform the unstructured (and largely untapped) health information to enable better care decisions, find clinical trials, and power research using real-world evidence. In addition, as the use of Invitae testing and the Ciitizen service expands, third-party access to consented genomic and other clinical data can be democratized to power a variety of applications that can enhance Invitae's business and growth strategy.

 

Transaction Terms

Under the terms of the agreement, Invitae will acquire Ciitizen for approximately $325 million (subject to adjustment), consisting of (i) approximately $125 million in cash and (ii) approximately 7,070,000 shares of Invitae common stock (based upon a trailing average closing price prior to the agreement date). Invitae will also issue approximately $225 million in restricted stock units (RSUs) to new employees who join Invitae in connection with its acquisition of Ciitizen. These RSUs will be granted under Invitae's 2015 Stock Incentive Plan, which is being amended and restated to increase a pool of shares of Invitae common stock thereunder which is used exclusively for the grant of inducement awards in compliance with New York Stock Exchange Rule 303A.08 ("Rule 303A.08"). These RSUs have been approved by the Invitae Board of Directors and will be made as an inducement material to each employee entering into employment with Invitae in reliance on the employment inducement exemption under Rule 303A.08. These RSUs will cover up to a total of approximately 8,125,000 shares of Invitae common stock (based upon a trailing average closing price prior to the agreement date) and will vest in tranches of one-third upon each of the first, second and third anniversaries of the date of grant, subject to acceleration in the event of a termination without cause by Invitae or a termination with good reason by a recipient. A total of 99 recipients will receive these RSUs, and Anil Sethi, the CEO and founder of Ciitizen, will receive RSUs with respect to approximately 2,011,000 shares of Invitae common stock.

 

The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close this month.

 

Conference Call and Webcast today at 8:30 a.m. ET / 5:30 a.m. PT

Management will host a conference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT to discuss the transaction. To register for the conference call, please use the link below. Upon registering, each participant will be provided with call details and a registrant ID.

 

The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website.

 

About Invitae
Invitae Corporation is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. 

 

About Ciitizen
Ciitizen is a patient-centric consumer health technology platform that enables patients to collect, store and share their medical records in a single location. Ciitizen developed proprietary machine learning and AI technologies to abstract critical information from unstructured health records to advance the understanding of diseases, match patients with potentially life-saving clinical trials, and enable better care decisions. Ciitizen also provides valuable big data analytics and data quality technologies to the network of Health Information Exchanges (HIEs) to produce research-ready, regulatory-grade data within minutes, instead of hours or days, and ensure HIEs can comply with the Information Blocking regulations.

Spotlight

Other News
Medical Devices

Medtronic receives CE Mark for its next generation Micra leadless pacing systems

Medtronic | January 05, 2024

Medtronic plc a global leader in healthcare technology, announced it has received CE Mark for its Micra™ AV2 and Micra™ VR2, the next generation of its industry-leading miniature, leadless pacemakers. Micra AV2 and Micra VR2, the world's smallest pacemakers, provide longer battery life and easier programming than prior Micra pacemakers, while still delivering the many benefits of leadless pacing such as reduced complications compared to traditional pacemakers.2 With approximately 40% more battery life compared to previous generations,1 Medtronic projects the battery life of Micra AV2 and Micra VR2 is nearly 16 and 17 years, respectively.3 This means more than 80% of patients who receive a Micra may only require one device for life.3 This CE Mark milestone follows U.S. Food and Drug Administration approval for the Micra AV2 and VR2 devices in 2023. In addition to size and longevity benefits, Micra devices are also the only leadless pacemakers with remote monitoring capabilities, which allow a doctor or clinic to check on a patient's heart device without the need for a patient to travel to their clinic for an in-person appointment. Other patient benefits of remote monitoring may include a reduction in hospitalizations and increase in sense of security.4,5 "For more than eight years, our Micra leadless pacemakers have provided meaningful benefits to people in Europe who require a pacemaker. Now, these patients have access to the latest leadless pacing technology that, for most of them, may be the only device they will ever need," said Robert C. Kowal, M.D., Ph.D., general manager, Cardiac Pacing Therapies within the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic. "The first generation of leadless Micra pacemakers demonstrated a significant reduction in major complications, and this next generation of Micra brings several additional benefits including greater longevity, and specifically for the Micra AV2, new algorithms to optimize AV synchrony at faster heart rates while requiring less in-office programming," said Prof. Dr. Christophe Garweg, Cardiologist at University Hospitals of Leuven, Belgium. "These advantages likely will expand the use of the leadless pacemaker to more patients." Globally, more than 200,000 patients have received Micra pacemakers.6 Comparable in size to a large vitamin, Micra pacemakers are less than one-tenth the size of traditional pacemakers. Unlike traditional pacemakers, Micra pacemakers do not require leads or a surgical "pocket" under the skin, so potential sources of complications related to leads and pockets are eliminated, and there is no visible sign of the device. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

Read More

Healthcare Analytics

SHL Medical partners with SteriPack Group to set up final assembly service

SHL Medical | January 24, 2024

SHL Medical, a world-leading solutions provider of advanced drug delivery systems and SteriPack Group, renowned global supplier of secondary packing and final assembly services to the pharmaceutical industry, enter a non-exclusive strategic partnership. Together, they aim to establish a pre-validated final assembly service at the SteriPack facility in Poland, enhancing the overall flexibility of supply chain strategies for their customers. In addition to SHL Medical's existing final assembly, labeling, and packaging­ services in the United States, this collaboration extends high-quality CMO options to Europe. Markus Puusepp, SHL Medical's Chief Growth Officer, expressed enthusiasm about the partnership, stating "This partnership is a significant addition to the Molly® platform value proposition. We share common values with SteriPack, from focus on the customer to a commitment to quality, making the decision to collaborate straightforward." Recognizing the importance of flexibility and time-to-market, especially in clinical production, the partnership with SteriPack will offer SHL Medical's customers highly flexible and personalized final assembly and packaging solutions. This is particularly beneficial for small batch handling in clinical supply and niche markets like rare diseases. Emphasizing the comprehensive capabilities of the Molly platform, SHL Medical aims to deliver right-sized solutions that ensure improved service, faster timelines, and a more streamlined supply chain for its diverse customer base. John Ward, SteriPack Group's VP Pharmaceutical Solutions commented "SteriPack Group looks forward to supporting SHL Medical and their customers in providing quality and flexible solutions to a fast- moving market. With an emphasis on creating service solutions designed around specific customer requirements, this partnership will make the process of working with the Molly® platform an easy decision." About SHL Medical As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by its company purpose – Enabling Patients' Independence – SHL Medical offers patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. It also offers final assembly, labeling, and packaging solutions for its drug delivery systems. In response to the rising trend in home therapy, SHL Medical has increased its developmental work in the digital healthcare sector to help improve the drug delivery ecosystem. Located across Switzerland, Taiwan, Sweden, and the US, SHL Medical's global team of experts collaborate seamlessly as one team in utilizing its comprehensive in-house manufacturing capabilities. Its solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into its designs and processes to contribute to a cleaner earth. About SteriPack Group SteriPack Group is a globally renowned contract packing and manufacturing organisation serving the pharmaceutical and medical device sectors respectively. With a strong emphasis on innovation, quality and compliance, SteriPack's services to the pharmaceutical industry include device design and development, final assembly, labelling, secondary packing, serialisation and aggregation of injectable formats including vials, pre-filled syringes, and autoinjectors. SteriPack's tailored customer-focused solutions make it an ideally suited supplier for small to medium-sized batch volumes required for a growing market of targeted therapies as well as clinical trials. Its proven capabilities in cleanroom assembly and labelling as well as secondary packing services for drug delivery systems and medical devices, combined with significant investment into growing cold chain storage capacity, have helped to make it a trusted partner to top global pharmaceutical companies.

Read More

Medical Devices

Canon Medical Systems and Olympus Announce Business Alliance regarding Endoscopic Ultrasound Systems

Canon Medical Systems | January 15, 2024

Canon Medical Systems Corporation and Olympus Corporation announced that we have reached an agreement to collaborate on Endoscopic Ultrasound Systems. Canon Medical will develop and manufacture diagnostic ultrasound systems used in Endoscopic Ultrasonography1 (EUS), and Olympus will perform the sales and marketing efforts. The aim of this collaboration between Canon's Aplio i8002 diagnostic ultrasound system for EUS and Olympus' Ultrasound Endoscope3 is to provide the market with advanced EUS equipment capable of delivering high-quality image diagnoses. Canon Medical and Olympus are focusing on technological advancements and enhancing diagnostic performance in the EUS field, with plans for global expansion, starting in Japan and Europe. Canon Medical has a history of more than 100 years in the diagnostic imaging systems business, including X-ray diagnostic systems, CT, MRI, and ultrasound diagnostic systems, and provides products and services to more than 150 countries and regions worldwide. Canon Medical has been a leading company in the development of diagnostic ultrasound systems since the 1960s and has pioneered the development of A-mode (Amplitude display mode) systems for neurosurgery and linear electronic scanning systems, among others. Canon Medical's strengths lie in its advanced ultrasound image quality and proprietary technologies, such as D-THI, an image quality enhancement technology, and SMI, an imaging technology that enables the delineation of extremely slow and fine blood flow, which has been difficult to image in the past. Olympus has contributed to elevating the standard of care through early detection, diagnosis and staging, and minimally invasive treatment since developing the world’s first practical gastrocamera. In the field of EUS, Olympus has worked closely with physicians to develop new equipment to enhance imaging and diagnostic methods and expand procedures, helping gain and maintain a high share of the global market. Through our collaboration, the two companies will achieve further qualitative improvements in the quality of images and performance in diagnosis and minimally invasive treatment of EUS, ultimately contributing to facilitate the early detection of diseases. Comment from Toshio Takiguchi, President and CEO, Canon Medical Systems Corporation “We have been promoting our business with diagnostic imaging at its core under the philosophy of 'Made for Life,' which expresses our desire to contribute to medical care that protects precious lives. We have a long history in diagnostic ultrasound systems and have developed unique technologies that contribute to the early detection of diseases in cooperation with doctors around the world. We are very pleased to collaborate with Olympus, a leading endoscope manufacturer, in the EUS field, which we have not been able to cover adequately until now, to deliver superior solutions to more patients.” Comment from Frank Drewalowski, Executive Officer and Endoscopic Solutions Division Head, Olympus Corporation “Olympus aims to improve patients’ quality of life through early diagnosis made available with Endoscopic Ultrasound Systems. In the field of EUS, diagnostic ultrasound systems are very important, and we are pleased to have a cooperative relationship with Canon Medical, which has advanced ultrasound imaging technology. Canon Medical and Olympus will continue to introduce products and technology that address the needs of the patients, healthcare professionals, and the broader medical industry.” This examination uses ultrasound attached to the tip of an endoscope to observe the outer organs (pancreas, gallbladder, bile ducts, liver, etc.) from the stomach and duodenum. Compared to the approach from the body surface, the target organs can be observed at close range, allowing detailed diagnosis with clearer images. In the diagnosis of pancreatic cancer, EUS is recognized as having the same diagnostic capability as contrast-enhanced CT and MRI in the "Guidelines for Pancreatic Cancer Treatment (2022)" in Japan. EUS-FNA (Endoscopic Ultrasonography-FNA: a test to collect tumor cells using an ultrasound endoscope) enables qualitative tissue diagnosis by minimally invasive cell and tissue collection and is established worldwide as a diagnostic method when pancreatic cancer is suspected. In addition to endoscopic retrograde cholangiopancreatography (ERCP), which is the first choice for stent placement for obstructive jaundice, endoscopic ultrasound-assisted biliary drainage (EUS-BD) using the EUS-FNA technique is now available. With the advent of these devices, the endoscopic treatment area of Interventional EUS has been attracting increasing attention in recent years. About Canon Medical Systems Canon Medical offers a full range of diagnostic medical imaging solutions including CT, Diagnostic and Interventional X-ray, Ultrasound and MR, as well as a full suite of Healthcare IT solutions, across the globe. In line with our continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features. At Canon Medical, we work hand in hand with our partners - our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life About Olympus At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world.

Read More

Health Technology

BroadcastMed Launches New Platform for Vision Portfolio of Products

BroadcastMed | January 25, 2024

BroadcastMed, the leading healthcare information marketplace that provides trusted clinical content, powerful engagement, and industry insights to healthcare professionals (HCPs), medical institutions and manufacturers, service providers, and pharmaceutical companies, is thrilled to announce the evolution of its Vision portfolio. PentaVision, powered by BroadcastMed, released a new digital platform designed to elevate the user experience for healthcare and optical professionals. Driven by many of the industry's leading Optometry and Ophthalmology publications, the platform leverages an intricate network that spans across their entire suite of Vision brands. The architecture was designed to provide HCPs with vibrant, interactive content within personalized user experiences. Real-time industry data has been optimized, ensuring that HCPs remain informed of the latest developments, trends, and breakthroughs in the field. With a user-centric design, the platform enables HCPs to navigate effortlessly, thereby saving time and enhancing efficiency in accessing the most pertinent and valuable content. This dedication to convenience fosters continuous learning, collaboration, and professional growth. "We are delighted about the positive impact this enhanced network will have on our partners' ability to connect with HCPs in a meaningful way," said Lee Schweizer, Chief Digital Officer, BroadcastMed. "With optimized architecture for improved search visibility, a network-buying approach for advertisers, and plans for dynamic content in 2024, we're excited to offer enhanced benefits for both advertisers and healthcare providers." "The new Retinal Physician website offers faster navigation, improved content, and a streamlined interface. I think the changes will be appreciated by everyone!" said Peter K. Kaiser, MD, Professor of Ophthalmology, Chaney Family Endowed Chair in Ophthalmology Research. BroadcastMed, together with 424 Capital, a growth capital partner, acquired PentaVision in August of 2022 to expand its healthcare audience and secure high-quality content across 11 brands in vision care. PentaVision's media brands are among the most respected and read brands globally, and include Contact Lens Spectrum, Corneal Physician, Eyecare Business, Glaucoma Physician, New Retinal Physician, Optometric Management, Ophthalmology Management, Ophthalmic Professional, Presbyopia Physician, and Retinal Physician. Underlining its commitment to evolving content distribution, expanding multichannel reach, fostering engaging live events and streaming experiences, and providing insightful data to HCPs and supporting organizations, BroadcastMed is dedicated to advancing the field of healthcare. About BroadcastMed BroadcastMed is the leading healthcare information marketplace that provides trusted clinical content, powerful engagement and industry insights to healthcare professionals, medical institutions and manufacturers, service providers and pharmaceutical companies. The company's integrated platform of digital, event, and publication solutions helps drive better dialogue, connectivity, and outcomes for the healthcare community.

Read More